The Russian Direct Investment Fund (RDIF) and Virchow Biotech have signed an agreement to annually produce up to 200 million doses of Russia’s Covid-9 vaccine Sputnik V in India.
Based on a proven and well-studied platform of human adenoviral vectors, Sputnik V uses two different vectors for the two jabs in a course of inoculation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The transfer of technology is anticipated to conclude in the second quarter of this year followed by a full-scale commercial production of the vaccine.
The Virchow Biotech capabilities will help the global supply of Sputnik V to RDIF’s international partners.
Russian Direct Investment Fund CEO Kirill Dmitriev said: “Vaccine partnerships are the only way to overcome the pandemic.
“The agreement with Virchow Biotech is an important step to facilitate the full-scale local production of the vaccine in India and to supply our international partners globally.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSputnik V is currently registered in 54 countries globally.
Last month, Mexican health regulator COFEPRIS authorised Sputnik V for emergency use after the country entered a contract to secure millions of vaccine doses.
On another note, Dyadic International (DYAI) is set to expand its partnership with South Korea’s Medytox to co-develop C1 manufactured Covid-19 vaccines and/or boosters.
If proven successful, these vaccines will be used against two or more of the existing and future Covid-19 variants.
Medytox Research and Development (R&D) senior executive vice-president and head Dr Gi-Hyeok Yang said: “Based on our experience and comparing the C1 technology platform against several other expression platforms such as CHO and insect cells, we believe that the fungi-derived C1 expression system is the most realistic technology to develop and manufacture multi-valent (i.e., tri-valent, and tetra-valent) vaccines rapidly and affordably against Covid-19 mutant viruses without the need for a large-scale bioreactor facility.”
